Pacira Pharmaceuticals Inc-DE
Slēgts
SektorsVeselības aprūpe
23.83 1.02
Pārskats
Akcijas cenas izmaiņa
24h
Min
23.4
Max
24.18
Ienākumi | 1.3M 2.9M |
|---|---|
Pārdošana | -19M 177M |
P/E Sektora vidējais | 174.692 50.958 |
EPS | 0.6 |
Peļņas marža | 1.644 |
Darbinieki | 825 |
EBITDA | 5M 30M |
Rekomendācijas | Pirkt |
|---|---|
Prognoze 12 mēnešiem | +26.54% upside |
Nākamie ieņēmumi | 2026. g. 4. aug. |
|---|
Tirgus kapitalizācija | -206M 894M |
|---|---|
Iepriekšējā atvēršanas cena | 22.81 |
Iepriekšējā slēgšanas cena | 23.83 |
Ziņu noskaņojums
By Acuity
67%
33%
295 / 342 Rangs Healthcare
Pacira Pharmaceuticals Inc-DE Grafiks
Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.
Par Pacira Pharmaceuticals Inc-DE
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.